Loading
Latest filing published 26 Nov 2024 for Lineage Cell Therapeutics, Inc., €8,474.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Jill Ann Howe across 2 companies, led by Biora Therapeutics, Inc. and Lineage Cell Therapeutics, Inc. The record holds 7 filings, for trades running from 3 November 2021 to 26 November 2024.
On the market, this insider has only ever bought: 2 purchases, €17k in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 4 share grants. Since January 2024: 2 purchases and no sales on the market.
The newest entry dates from 26 November 2024: an open-market purchase of €8,474, in Lineage Cell Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations